Mira Pharmaceuticals (MIRA) Non Operating Income (2024 - 2025)
Mira Pharmaceuticals' (MIRA) quarterly Non Operating Income came in at -$158494.0 in Q4 2025, down 515.94% year-on-year from $38105.0 in Q4 2024, and down 188.39% quarter-over-quarter from $179312.0 in Q3 2025.
Mira Pharmaceuticals (MIRA) Non Operating Income (2024 - 2025) Analysis & Trends
Mira Pharmaceuticals has disclosed Non Operating Income across 2 years of filings, most recently posting -$158494.0 for Q4 2025.
- Non Operating Income for Q4 2025 came in at -$158494.0, down 515.94% year-over-year; the trailing twelve-month figure through Dec 2025 was $58816.0 (changed N/A YoY), and the FY2025 annual result was $50627.0, down 69.44% from the prior year.
- Non Operating Income came in at -$158494.0 for Q4 2025 at Mira Pharmaceuticals, down from $179312.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $179312.0 in Q3 2025 to a low of -$158494.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 195.49 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -65.00 Mn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -294.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -2.31 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -32.00 Mn |
| 10 | Mira Pharmaceuticals | 22.73 Mn | 11.70 Mn | - | -158,494.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -158,494.00 |
| Sep 30, 2025 | 179,312.00 |
| Jun 30, 2025 | -107.00 |
| Dec 31, 2024 | 38,105.00 |
| Sep 30, 2024 | 37,752.00 |